Literature DB >> 18353945

HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control.

Brinda Emu1, Elizabeth Sinclair, Hiroyu Hatano, April Ferre, Barbara Shacklett, Jeffrey N Martin, J M McCune, Steven G Deeks.   

Abstract

A rare subset of human immunodeficiency virus (HIV)-infected individuals maintains undetectable HIV RNA levels without therapy ("elite controllers"). To clarify the role of T-cell responses in mediating virus control, we compared HLA class I polymorphisms and HIV-specific T-cell responses among a large cohort of elite controllers (HIV-RNA < 75 copies/ml), "viremic" controllers (low-level viremia without therapy), "noncontrollers" (high-level viremia), and "antiretroviral therapy suppressed" individuals (undetectable HIV-RNA levels on antiretroviral therapy). The proportion of CD4(+) and CD8(+) T cells that produce gamma interferon (IFN-gamma) and interleukin-2 (IL-2) in response to Gag and Pol peptides was highest in the elite and viremic controllers (P < 0.0001). Forty percent of the elite controllers were HLA-B*57 compared to twenty-three percent of viremic controllers and nine percent of noncontrollers (P < 0.001). Other HLA class I alleles more common in elite controllers included HLA-B*13, HLA-B*58, and HLA-B*81 (P < 0.05 for each). Within elite and viremic controller groups, those with protective class I alleles had higher frequencies of Gag-specific CD8(+) T cells than those without these alleles (P = 0.01). Noncontrollers, with or without protective alleles, had low-level CD8(+) responses. Thus, certain HLA class I alleles are enriched in HIV controllers and are associated with strong Gag-specific CD8(+)IFN-gamma(+)IL-2(+) T cells. However, the absence of evidence of T cell-mediated control in many controllers suggests the presence of alternative mechanisms for viral control in these individuals. Defining mechanisms for virus control in "non-T-cell controllers" might lead to insights into preventing HIV transmission or preventing virus replication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353945      PMCID: PMC2395228          DOI: 10.1128/JVI.02176-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children.

Authors:  P J Goulder; C Brander; K Annamalai; N Mngqundaniso; U Govender; Y Tang; S He; K E Hartman; C A O'Callaghan; G S Ogg; M A Altfeld; E S Rosenberg; H Cao; S A Kalams; M Hammond; M Bunce; S I Pelton; S A Burchett; K McIntosh; H M Coovadia; B D Walker
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.

Authors:  G M Ortiz; M Wellons; J Brancato; H T Vo; R L Zinn; D E Clarkson; K Van Loon; S Bonhoeffer; G D Miralles; D Montefiori; J A Bartlett; D F Nixon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

3.  Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia.

Authors:  Jaap Goudsmit; Johannes A Bogaards; Suzanne Jurriaans; Hanneke Schuitemaker; Joep M A Lange; Roel A Coutinho; Gerrit Jan Weverling
Journal:  AIDS       Date:  2002-03-29       Impact factor: 4.177

4.  HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors.

Authors:  Stephen A Migueles; Alisha C Laborico; W Lesley Shupert; M Shirin Sabbaghian; Ronald Rabin; Claire W Hallahan; Debbie Van Baarle; Stefan Kostense; Frank Miedema; Mary McLaughlin; Linda Ehler; Julia Metcalf; Shuying Liu; Mark Connors
Journal:  Nat Immunol       Date:  2002-10-07       Impact factor: 25.606

5.  The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.

Authors:  F García; M Plana; G M Ortiz; S Bonhoeffer; A Soriano; C Vidal; A Cruceta; M Arnedo; C Gil; G Pantaleo; T Pumarola; T Gallart; D F Nixon; J M Miró; J M Gatell
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

6.  Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS.

Authors:  X Gao; G W Nelson; P Karacki; M P Martin; J Phair; R Kaslow; J J Goedert; S Buchbinder; K Hoots; D Vlahov; S J O'Brien; M Carrington
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

7.  Persistent numbers of tetramer+ CD8(+) T cells, but loss of interferon-gamma+ HIV-specific T cells during progression to AIDS.

Authors:  Stefan Kostense; Kristin Vandenberghe; Jeanine Joling; Debbie Van Baarle; Nening Nanlohy; Erik Manting; Frank Miedema
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

8.  Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.

Authors:  Florencia Pereyra; Marylyn M Addo; Daniel E Kaufmann; Yang Liu; Toshiyuki Miura; Almas Rathod; Brett Baker; Alicja Trocha; Rachel Rosenberg; Elizabeth Mackey; Peggy Ueda; Zhigang Lu; Daniel Cohen; Terri Wrin; Christos J Petropoulos; Eric S Rosenberg; Bruce D Walker
Journal:  J Infect Dis       Date:  2008-02-15       Impact factor: 5.226

9.  Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS.

Authors:  Maureen P Martin; Xiaojiang Gao; Jeong-Hee Lee; George W Nelson; Roger Detels; James J Goedert; Susan Buchbinder; Keith Hoots; David Vlahov; John Trowsdale; Michael Wilson; Stephen J O'Brien; Mary Carrington
Journal:  Nat Genet       Date:  2002-07-22       Impact factor: 38.330

10.  The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences.

Authors:  Stephen A Migueles; Alisha C Laborico; Hiromi Imamichi; W Lesley Shupert; Cassandra Royce; Mary McLaughlin; Linda Ehler; Julia Metcalf; Shuying Liu; Claire W Hallahan; Mark Connors
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more
  135 in total

1.  Interleukin-2 production by polyfunctional HIV-1-specific CD8 T cells is associated with enhanced viral suppression.

Authors:  Olusimidele T Akinsiku; Anju Bansal; Steffanie Sabbaj; Sonya L Heath; Paul A Goepfert
Journal:  J Acquir Immune Defic Syndr       Date:  2011-10-01       Impact factor: 3.731

2.  For protection from HIV-1 infection, more might not be better: a systematic analysis of HIV Gag epitopes of two alleles associated with different outcomes of HIV-1 infection.

Authors:  Ma Luo; Christina A Daniuk; Tamsir O Diallo; Rupert E Capina; Joshua Kimani; Charles Wachihi; Makubo Kimani; Thomas Bielawny; Trevor Peterson; Mark G R Mendoza; Sandra Kiazyk; T Blake Ball; Francis A Plummer
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

3.  Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses.

Authors:  Zaza M Ndhlovu; Jacqueline Proudfoot; Kevin Cesa; Donna Marie Alvino; Ashley McMullen; Seanna Vine; Eleni Stampouloglou; Alicja Piechocka-Trocha; Bruce D Walker; Florencia Pereyra
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

4.  HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses.

Authors:  April L Ferre; Peter W Hunt; Delandy H McConnell; Megan M Morris; Juan C Garcia; Richard B Pollard; Hal F Yee; Jeffrey N Martin; Steven G Deeks; Barbara L Shacklett
Journal:  J Virol       Date:  2010-08-18       Impact factor: 5.103

5.  Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers.

Authors:  April L Ferre; Donna Lemongello; Peter W Hunt; Megan M Morris; Juan Carlos Garcia; Richard B Pollard; Hal F Yee; Jeffrey N Martin; Steven G Deeks; Barbara L Shacklett
Journal:  J Virol       Date:  2010-07-28       Impact factor: 5.103

6.  Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus.

Authors:  Karen A O'Connell; Timothy P Brennan; Justin R Bailey; Stuart C Ray; Robert F Siliciano; Joel N Blankson
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

Review 7.  Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV.

Authors:  George Makedonas; Michael R Betts
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

8.  Impaired replication capacity of acute/early viruses in persons who become HIV controllers.

Authors:  Toshiyuki Miura; Zabrina L Brumme; Mark A Brockman; Pamela Rosato; Jennifer Sela; Chanson J Brumme; Florencia Pereyra; Daniel E Kaufmann; Alicja Trocha; Brian L Block; Eric S Daar; Elizabeth Connick; Heiko Jessen; Anthony D Kelleher; Eric Rosenberg; Martin Markowitz; Kim Schafer; Florin Vaida; Aikichi Iwamoto; Susan Little; Bruce D Walker
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

9.  Secretion of MIP-1β and MIP-1α by CD8(+) T-lymphocytes correlates with HIV-1 inhibition independent of coreceptor usage.

Authors:  Kevin O Saunders; Cavin Ward-Caviness; Robert J Schutte; Stephanie A Freel; R Glenn Overman; Nathan M Thielman; Coleen K Cunningham; Thomas B Kepler; Georgia D Tomaras
Journal:  Cell Immunol       Date:  2010-10-27       Impact factor: 4.868

10.  Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification.

Authors:  M Christian Tjiam; James P A Taylor; Mazmah A Morshidi; Lucy Sariputra; Sally Burrows; Jeffrey N Martin; Steven G Deeks; Dino B A Tan; Silvia Lee; Sonia Fernandez; Martyn A French
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.